The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.